GlassScriptPhysician profile
Cassidy Johnston
NPI 1831830694
$5,071.93
in general payments reported to CMS, 2019-2025
23 companies · $2,482 in 2025
The $2,482 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $724 · 2024: $1,866 · 2025: $2,482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,810 · Education: $262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,810.30 |
| Education | $261.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,132.27 | 2024-2025 | Tremfya |
| Abbvie INC. | $1,034.94 | 2023-2025 | |
| Genzyme Corporation | $556.33 | 2023-2025 | |
| Galderma Laboratories, L.P. | $386.63 | 2023-2025 | Nemluvio, Aklief |
| Dermavant Sciences, INC. | $245.52 | 2023 | Vtama |
| Novartis Pharmaceuticals Corporation | $213.51 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $190.97 | 2024-2025 | Tremfya |
| Lilly USA, LLC | $183.45 | 2024-2025 | Ebglyss, Taltz, Olumiant |
| Ucb, INC. | $174.35 | 2023-2025 | Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.90 | 2023-2024 | Spevigo, Cyltezo |
| E.R. Squibb & Sons, L.L.C. | $160.66 | 2024-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $143.11 | 2023-2025 | Zoryve |
| Organon LLC | $110.73 | 2024-2025 | Hadlima |
| Sanofi-Aventis U.S. LLC | $72.00 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $55.95 | 2025 | Dupixent |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $49.01 | 2025 | Anzupgo |
| Sandoz INC. | $34.89 | 2024 | Hyrimoz |
| Amgen INC. | $34.61 | 2025 | Otezla |
| Blueprint Medicines Corporation | $32.72 | 2025 | Ayvakit |
| Pfizer INC. | $30.75 | 2025 | |
| Sun Pharmaceutical Industries INC. | $30.75 | 2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $22.45 | 2024 | Targretin |
| Pharming Healthcare, INC. | $15.43 | 2025 | Ruconest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cassidy Johnston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.